Ruben Tommasi

Ruben Tommasi is an experienced Chief Scientific Officer currently serving at Entact Bio since September 2024, following a tenure in the same role at Dunad Therapeutics from September 2022 to August 2024 and at Entasis Therapeutics from May 2015 to August 2022. Prior to these positions, Ruben Tommasi held the title of Executive Director - Infection Chemistry at AstraZeneca from May 2011 to May 2015. Ruben Tommasi also contributed significantly to the Novartis Institutes of Biomedical Research between January 2004 and May 2011 as Head of Infectious Disease Chemistry and Head of Lead Synthesis & Chemogenetics, and began a research career within Novartis from 1994 to 2003 as a Research Investigator. Ruben Tommasi's earlier experiences include roles at Upjohn and the University of Colorado Boulder as a Postdoctoral researcher. Academic credentials include a Ph.D. in Organic Chemistry and a B.S. in Chemistry from the University at Albany, completed between 1983 and 1992.